Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148742 | 0.93 | KMT2A (0.59) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4135659 | 0.90 | SLC6A9 (0.55) | MEN1KMT2AIGF1RSMN1; SMN2LMNA | |
| SCHEMBL4136263 | 0.88 | SLC6A9 (0.63) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4144684 | 0.86 | CACNA2D1 (0.57) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4157303 | 0.86 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4143550 | 0.84 | SLC6A9 (0.54) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4151706 | 0.84 | CACNA2D1 (0.56) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL4143556 | 0.84 | SLC6A9 (0.63) | MEN1KMT2AIGF1RSLC6A9 | |
| SCHEMBL4143551 | 0.84 | SLC6A9 (0.63) | MEN1KMT2AIGF1RSLC6A9 | |
| SCHEMBL4143558 | 0.84 | SLC6A9 (0.63) | MEN1KMT2AIGF1RSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8183244-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | disclosed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885IGF1R 2343/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | MEN1 2632/4885KMT2A 947/4885IGF1R 2188/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885IGF1R 2343/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885IGF1R 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.